We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Merck (MRK - Free Report) closed the most recent trading day at $128.66, moving +2.56% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.05%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, lost 0.24%.
The stock of pharmaceutical company has risen by 4.64% in the past month, leading the Medical sector's gain of 4.42% and the S&P 500's loss of 1.42%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on August 4, 2026. The company's upcoming EPS is projected at $2.1, signifying a 1.41% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $16.28 billion, up 3.02% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $5.17 per share and revenue of $66.79 billion. These totals would mark changes of -42.43% and +2.73%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Merck. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Merck is currently a Zacks Rank #3 (Hold).
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 24.27. Its industry sports an average Forward P/E of 15.77, so one might conclude that Merck is trading at a premium comparatively.
Meanwhile, MRK's PEG ratio is currently 2.82. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. MRK's industry had an average PEG ratio of 2.73 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 95, placing it within the top 39% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK - Free Report) closed the most recent trading day at $128.66, moving +2.56% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.05%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, lost 0.24%.
The stock of pharmaceutical company has risen by 4.64% in the past month, leading the Medical sector's gain of 4.42% and the S&P 500's loss of 1.42%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on August 4, 2026. The company's upcoming EPS is projected at $2.1, signifying a 1.41% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $16.28 billion, up 3.02% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $5.17 per share and revenue of $66.79 billion. These totals would mark changes of -42.43% and +2.73%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Merck. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Merck is currently a Zacks Rank #3 (Hold).
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 24.27. Its industry sports an average Forward P/E of 15.77, so one might conclude that Merck is trading at a premium comparatively.
Meanwhile, MRK's PEG ratio is currently 2.82. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. MRK's industry had an average PEG ratio of 2.73 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 95, placing it within the top 39% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.